Core Scientific's stock has maintained Nasdaq compliance while traders refocus on its development pipeline.
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) stock has been trading up 7.76 percent amid heightened optimism over its latest biotech developments.
Nasdaq has confirmed that Scinai Immunotherapeutics is back in full compliance with the $1.00 minimum bid price rule, removing the immediate threat of delisting. Compliance was regained after 19 consecutive trading days with the share price holding above $1.00, a development that signals firmer price support for SCNI. The company continues to advance its NanoAb immunology programs, which remain the core scientific driver behind the stock. Alongside the pipeline, management is pushing to grow Scinai's contract development and manufacturing (CDMO) operations as an additional revenue engine.
On Tuesday, October 13, 2026, SCNI was trending up 7.76 percent in live trading at 15:04:12 EDT.
SCNI has traded like a classic small-cap biotech battleground. Over recent sessions, the stock has swung from a high near $2.33 in early premarket trading to a close around $1.25 on October 13, 2026, a sharp intraday round-trip that underscores the name's continued volatility. On the daily chart, SCNI has pulled back from the $1.90–$2.00 area seen in late September toward the low $1s. The stock has held above the key $1.00 Nasdaq threshold, which now matters more than ever following the compliance regain. For short-term traders, the $1 area is the psychological floor to watch.
Fundamentally, Scinai Immunotherapeutics is still in build-out mode. Revenue sits near $1.31 million with a price-to-sales ratio of about 1.22, which is low for a speculative biotech. Book value per share is roughly $1.83, and SCNI trades below that level, suggesting a discounted balance sheet. At the same time, returns on assets and equity are deeply negative, indicating the company is far from profitability. This combination creates a high-risk, high-reward biotech profile in which news, liquidity, and sentiment drive trading.
Traders focus on clear catalysts, and SCNI has just removed a significant negative one. Nasdaq has officially closed its non-compliance matter, taking the immediate delisting risk off the table. When a small-cap biotech trades under delisting pressure, every downtick feels heavier, and many funds and retail traders avoid names that might be removed from a major exchange. With SCNI back in good standing, the narrative can shift from survival back toward execution.
That is where the NanoAb programs come in. Scinai is developing these next-generation antibody treatments while also pursuing its CDMO operations. The NanoAb programs represent the long-term scientific upside, while CDMO services have the potential to provide steadier revenue if Scinai can win and retain contracts.
The intraday chart on October 13, 2026, illustrates how the market is processing this news. SCNI spiked from roughly $1.13 at 07:00 to above $3.00 in premarket trading, then faded sharply back into the $1 range. Such a liquidity burst is typical when a headline, like confirmed Nasdaq compliance, coincides with a thin float and a heavy day-trader presence.
With Nasdaq compliance restored, SCNI enters a new phase. The company is no longer shadowed by the threat of removal from a major exchange, which alone may help stabilize trader participation. The spotlight now returns to execution: advancing the NanoAb immunology pipeline and scaling the CDMO business.
The company holds about $11.6 million in total assets and roughly $8.1 million in equity, with 31 employees. Returns on assets of around -35% and a highly negative return on equity show how early and risky the story remains. Trading below book value while holding above $1.00 sets up a contest between value-focused biotech traders and those wary of continued losses.